SRC Signaling in Cancer and Tumor Microenvironment


CANER A. , Asik E., Ozpolat B.

TUMOR MICROENVIRONMENT: SIGNALING PATHWAYS, PT B, cilt.1270, ss.57-71, 2021 (SCI İndekslerine Giren Dergi) identifier

  • Cilt numarası: 1270
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1007/978-3-030-47189-7_4
  • Dergi Adı: TUMOR MICROENVIRONMENT: SIGNALING PATHWAYS, PT B
  • Sayfa Sayıları: ss.57-71

Özet

Pioneering experiments performed by Harold Varmus and Mike Bishop in 1976 led to one of the most influential discoveries in cancer research and identified the first cancer-causing oncogene called Src. Later experimental and clinical evidence suggested that Src kinase plays a significant role in promoting tumor growth and progression and its activity is associated with poor patient survival. Thus, several Src inhibitors were developed and approved by FDA for treatment of cancer patients. Tumor microenvironment (TME) is a highly complex and dynamic milieu where significant cross-talk occurs between cancer cells and TME components, which consist of tumor-associated macrophages, fibroblasts, and other immune and vascular cells. Growth factors and chemokines activate multiple signaling cascades in TME and induce multiple kinases and pathways, including Src, leading to tumor growth, invasion/metastasis, angiogenesis, drug resistance, and progression. Here, we will systemically evaluate recent findings regarding regulation of Src and significance of targeting Src in cancer therapy.